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Abstract 
AIM: To determine the distribution of vancomycin MIC and the frequency of S. aureus strains with reduced 
vancomycin susceptibility among Methicillin-Resistant Staphylococcus aureus (MRSA) isolates. 
METHODS: MRSA isolates (n = 100) were tested for reduced susceptibility to vancomycin using  MIC broth 
microdilution method (BMD), vancomycin screening agar with different vancomycin concentrations with and 
without casein, and Vitek 2 system. 
RESULTS: BMD detected (22%) vancomycin-intermediate S. aureus (VISA) and (78%) vancomycin-susceptible 
S. aureus (VSSA) but couldn’t detect nine (Heterogeneous VISA) (hVISA)   isolates (9%) with MIC ≤ 2 µg/ml that 
grew on screening agar 4 µg/ml or 6 µg/ml. Adding casein to vancomycin screening agar increased detection rate 
of VISA by 4.5%.  Screening agar with 6 µg/ml vancomycin overall detection rate for VISA was 95.45%. Probable 
‘pre-hVISA’isolates (17%) showed growth on vancomycin screening agar 2 µg/ml with casein. Vitek 2 system 
failed to detect any VISA isolates. 
CONCLUSION: Vancomycin screening agar; 2 µg/ml and (4 and 6 µg/ml) were able to detect; probable “pre 
hVISA and (hVISA and VISA) isolates respectively based on their BMD MIC values. Decreased vancomycin 
susceptibility in MRSA isolates might be related to MIC creep. Analysis of vancomycin MIC values over longer 
periods is recommended to further study this phenomenon and its impact on vancomycin treatment failure. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Staphylococcus aureus is a virulent 
microorganism responsible for many serious 
infections among the general population. The 
emergence of vancomycin resistance in S. aureus has 
been anticipated since vancomycin-resistant 
enterococci (VRE) has been recognised. Hiramatsu et 
al. in 1997 described the first documented case of 
infection caused by S. aureus with reduced 
susceptibility to vancomycin [1].  
Reduced susceptibility could be either due to 
strains that showed intermediate resistance to 
vancomycin with MIC 4-8 µg/mL [vancomycin 
intermediate S. aureus (VISA)] or heteroresistant 
strains (Heterogeneous VISA) (h-VISA) that are 
defined as strains with minimal inhibitory 
concentrations (MICs) within the susceptible range 
(MIC ≤ 2 μg/ml), but containing subpopulations of cells 
in the vancomycin-intermediate range (VISA, MIC 4-
8 μg/ml) These strains have been described for both 
MRSA and methicillin-susceptible S. aureus (MSSA) 
respectively [2]. 
 There has been special interest in 
vancomycin MIC creep phenomenon that was 
associated with greater rates of complications, and 
vancomycin therapeutic failures with vancomycin 
MICs within the susceptible range (MICs of 1-2 mg/L) 
[3], [4], [5]. Unfortunately, there has been uncertainty 
regarding optimal laboratory detection of S. aureus 
with reduced susceptibility to vancomycin [6].  
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Center for Disease Control and Prevention 
(CDC) in 2012 recommended that screening of VISA 
should be done by MIC method plus vancomycin 
screening agar method with 6ug of vancomycin per 
ml, but this is not reliable to detect all VISA; some 
strains for which the vancomycin MICs are 4 ug/ml will 
fail to grow [7], [8].  
Screening for h-VISA by the population 
analysis profile-area under the curve (PAP-AUC) 
method has been the most reliable and reproducible 
approach but is labour-intensive, costly, and 
unsuitable for routine use in clinical laboratories [9], 
[10]. 
Moreover, standardized reference methods 
for susceptibility testing, such as CLSI broth 
microdilution, agar dilution, and standard Etest 
methods, can detect VISA but fail to detect h-VISA 
due to several factors as small inoculum size, the 
relatively poor support of growth on Mueller-Hinton 
agar plates, the slow growth of h-VISA strains and its 
unique pleomorphic features, such as small-colony 
variant [9], [11]. 
Satola et al. showed that the use of BHI 
screen agar with 4 μg/ml vancomycin with increase 
incubation time to 48 hours and the addition of casein 
could increase the sensitivity and specificity for 
detection of VISA and may be useful for clinical 
detection of h-VISA [12].  
The study aimed to determine the distribution 
of vancomycin MIC, and the frequency of S. aureus 
strains with reduced vancomycin susceptibility among 
Methicillin-Resistant Staphylococcus aureus (MRSA) 
isolates. 
 
 
Materials and Methods 
 
The study included 100 MRSA isolates 
analysed by Kirby Bauer disc diffusion method [13] 
recovered from different specimens referred to Central 
Microbiology Laboratory of Ain Shams University 
Hospitals for routine culture and sensitivity. Isolates 
were collected throughout four months from January 
till April 2017 and were preserved on tryptone soy 
broth with 15% glycerol at -80°C until use.  
Detection of MRSA with reduced susceptibility 
to vancomycin was performed using vancomycin 
screening agar with different vancomycin 
concentrations 2, 4, and 6 µg/ml with and without 
casein and compared to MIC broth microdilution 
method for vancomycin (BMD) [13]. Finally, MIC 
susceptibility testing for MRSA isolates was performed 
by Vitek 2 automated system (Biomerieux, France). 
Brain heart infusion (BHI) agar without casein 
(Oxoid, UK) was prepared according to the 
manufacturer's instructions and BHI agar with casein 
was similarly prepared but with the addition of eight 
gram pancreatic digest of casein (Sigma Aldrich, 
USA) to every 500 ml of media [12]. A stock solution 
of vancomycin was prepared by dissolving 500 mg of 
vancomycin powder in 10 ml of sterile distilled water 
(final concentration was 50 mg/ml). At the time of 
media preparation, further dilution of 1:10 was done 
twice to produce a working solution of 0.5 mg/ml 
vancomycin. For the final preparation of vancomycin 
screening agar with and without casein; six ml, four ml 
and two ml of 500 ml prepared media were removed 
under complete aseptic precautions and replaced by 6 
ml, 4 ml and 2 ml of working solution of vancomycin to 
prepare Vancomycin screening agar with 6 g/ml, 4 
g/ml and 2 g/ml respectively. 
All isolates were subcultured by taking a small 
piece of a frozen organism with a sterile loop and 
plated twice onto blood agar plates. The used vial was 
returned immediately to the deep freezer to be used if 
needed as repeated thawing and re-freezing can 
reduce the viability of the organism. The cultivated 
plates were incubated aerobically at 35C for 24 
hours. Two to three colonies were picked up by the 
sterile loop and adjusted to 0.5 McFarland standards 
in 5 ml sterile tubes. Quadruplicate technique was 
performed (i.e. four droplets, 10ul each, from 0.5 
McFarland MRSA suspension, was dropped by a 
pipette onto the 2, 4, and 6 vancomycin screening 
agars) and the plates were incubation for a full 48 
hours at 35C to enhance the sensitivity of detection 
of MRSA with vancomycin reduced susceptibility [12]. 
Plates were examined at 24 and 48 hours. 
Vancomycin-Resistant Enterococcus Faecalis ATCC 
51299 and Staphylococcus aureus ATCC 25923 
(NAMRU-3) were used as positive and negative 
controls respectively. 
No growth in any of the four droplets was 
denoted as sensitive to vancomycin. Growth in any of 
the four droplets was considered as MRSA with 
vancomycin reduced susceptibility.  
The broth microdilution method was used for 
determination of the MICs of vancomycin [14]. 
Vancomycin suspension used was prepared by 
dissolving 500 mg of vancomycin powder in 10 ml of 
sterile distilled water (50 mg/ml), then further dilution 
1:10 was done twice (0.5 mg/ml ). From the prepared 
dilution, 640 l was added to 10 ml of D.W to reach a 
final concentration of 32 g/ml vancomycin.  
Serial two-fold dilution of the prepared 
vancomycin concentration was carried in a 96 well 
plate. Fifty microliters of double-strength Muller Hinton 
Broth (MHB), 50 l of the antibiotic dilutions, and (5 l 
of the organism suspension adjusted to 0.5 McFarland 
standards and then diluted 1:20) were mixed and 
incubated at 35C for 24 hours. MICs; ≤ 2 µg/ml is 
considered as sensitive, 4-8 µg/ml as VISA and ≥ 16 
µg/ml as vancomycin resistant S. aureus (VRSA) 
(Figure 1). 
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 Susceptibility testing on Vitek 2 system was 
performed with AST PG 76 cards according to the 
manufacturer’s instructions, and susceptibility 
breakpoints of Staphylococcus aureus were interpreted 
per CLSI 2015 [13]. 
 
 
Results 
 
Broth microdilution (BMD) method (Figure 1) 
revealed that, out of 100 MRSA isolates, 22/100 
(22%) were VISA (14/22 VISA with MIC = 8 µg/ml and 
8/22 VISA with MIC = 4 µg/ml) and 78/100 (78%) 
were VSSA (VSSA MIC ≤ 2 µg/ml). 
 
Figure 1: Broth microdilution plate for detection of vancomycin 
susceptibility in MRSA isolates; A12 to G12 are negative growth 
control wells. H1 to H11 wells are positive growth control wells. MIC 
of vancomycin for isolate; 4 (well E4) is 2 µg/ml, 5 (well E5) is 2 
µg/ml (VSSA), 6 (well D6) is 4 µg/ml and for isolate 8 (well C8) is 8 
µg/ml (VISA) 
 
In vancomycin screening agar method, h-
VISA was reported if one or two colonies on at least one 
droplet showed growth on screening agar with 4 µg/ml or 
6 µg/ml [12]. Among MRSA isolates that showed MIC ≤ 
2 µg/ml by BMD; 9 isolates (9%) grew on screening agar 
4 µg/ml or 6 µg/ml and were designated as h-VISA 
(Figure 2). 
 
Figure 2: Vancomycin screening agar 6 µg/ml with casein; isolate 
[23] shows the growth of hVISA. Isolate [24] shows no growth 
(VSSA) 
 
Seventeen isolates with susceptible MIC by 
BMD (17%) showed growth on vancomycin screening 
agar 2 µg/ml, six out of them with MIC of 2 µg/ml by 
BMD. These isolates were considered as probable ‘pre-
hVISA’, which represent small subpopulations of cells 
capable of growth in the presence of 2-4 mg/L 
vancomycin [14] (Table 1 and Figure 3). 
Table 1: Detection rate of MRSA with reduced susceptibility to 
vancomycin among 100 tested isolates 
BMD MIC Vancomycin screening Agar  
VISA (MIC 4-8) VSSA (MIC ≤ 2 µg/ml) 
0 52 (52%) No growth 
0 17 (17%) 2 µg/ml 
(probable pre-hVISA) 
22 (22%) 9 (9%) 
hVISA 
4 µg/ml or 6 µg/ml 
22 (22%) 78 (78%) Total 
 
All of the results of screening agar with and 
without casein were similar except for two isolates; 
one isolate showed growth on screening agar with 4 
µg/ml, with casein but not in that without casein, and 
one more isolate grew on screening agar 2 µg/ml 
without casein only after 48 hours. So, adding casein 
to vancomycin screening agar increased detection rate 
of VISA by 4.5% (only one VISA out of 22). Screening 
agar with 6 µg/ml vancomycin (with and without 
casein showed similar results) detected 7 out of 8 
VISA with BMD MIC equal to 4 µg/ml (87.5%) and 14 
out of 14 with BMD MIC equal to 8 µg/ml (100%), with 
overall detection rate of VISA 95.45% (Table 2).  
 
Figure 3: Results of Broth microdilution and vancomycin screening 
agar among 100 tested isolates 
 
Increasing incubation time did not increase the 
detection rate for vancomycin with reduced susceptibility 
among screening agar with casein and only affected one 
isolate grown on 2 µg/ml screening agar without casein 
(Table 2).  
Table 2 shows vancomycin MIC results using 
Broth microdilution and vancomycin screening agar. It 
is noted that Broth microdilution method was not able 
to detect nine (9) h-VISA isolates. 
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Table 2: Vancomycin MIC results using Broth microdilution 
and vancomycin screening agar for detection of MRSA with 
reduced susceptibility to vancomycin 
Vancomycin screening agar MIC  
 
 
BMD 
MIC 
 
> 6 µg/ml > 4 µg/ml-< 6 
µg/ml 
> 2 µg/ml (< 4 
µg/ml) 
No growth 
( < 2 µg/ml) 
with and 
without casein 
Without* 
casein 
With* 
casein 
Without* 
casein 
With* 
casein 
Without 
casein 
With 
casein* 
7 7 0 0 10 + 1● 11 52 MIC 
≤ 1  
S
e
n
s
it
iv
e
 
2 2 0 0 6* 6 0 MIC 
2 
7 7 0 1 0 0 0 MIC 
4 
In
te
rm
e
-
d
ia
te
 
14 14 0 0 0 0 0 MIC 
8 
30 30 0 1 16 + 1● 17 52 Total  
*No difference between 24 and 48 hours; ●the Only one showed no growth at 24 hours but 
detected at 48h. 
 
All of MRSA isolates (100%) were susceptible 
for both vancomycin and linezolid by VITEK 2 system. 
(Figure 4) shows the result of susceptibility testing for 
MRSA isolates on the Vitek 2 system. 
 
 
Figure 4: Result of susceptibility testing for 100 MRSA isolates 
using AST GP 76 cards on Vitek 2 system [14] 
 
 
Discussion 
 
Overuse of vancomycin has led to the 
development of a selective pressure over time with 
the result of the emergence of S. aureus with reduced 
vancomycin susceptibility. The emergence of MRSA 
with reduced susceptibility to vancomycin is 
worrisome as the available drugs for MRSA treatment 
are limited [6].  
We report 22% VISA isolates by broth 
microdilution method. Vaudaux et al. reported that 
Broth microdilution assay led to under detection of the 
vancomycin-intermediate S. aureus VISA) phenotype, 
yielding only three VISA isolates, for which 
vancomycin MICs were 4 μg/ml compared to 8 and 19 
VISA isolates detected by microdilution and agar 
testing, respectively [14].  
In the present study, among the MRSA isolates 
that showed MIC less than or equal to 2 µg/ml by BMD; 
(9%) of h-VISA isolates showed growth on screening 
agar 4 µg/ml or 6 µg/ml. Whereas, (17%) of isolates with 
susceptible MIC by BMD showed growth on vancomycin 
screening agar 2 µg/ml (probable ‘pre-hVISA’) [15]. The 
pre-hVISA strains may be correlated with the ‘MIC 
creep’ phenomenon observed in hospitals where anti-
MRSA chemotherapy is frequently implemented [15]. 
Lodise et al. observed that patients with 
MRSA bloodstream infections with elevated 
vancomycin MICs but within the susceptible range (≥ 
1.5 mg/mL) had higher probabilities of recurrent 
bacteremia and longer hospital stays [16]. Sakoulas et 
al. reported that the likelihood of treatment success is 
significantly lower in patients with MRSA isolate with a 
vancomycin MIC of 1-2 mg/mL compared with 
patients infected by isolates with a vancomycin MIC ≤ 
1.5 mg/Ml [17]. Edwards et al. suggested lowering 
vancomycin breakpoints further, to avoid clinical 
failure and the increased risk of mortality [4]. 
Satola et al., tested 140 MRSA blood isolates 
with vancomycin MICs 2 µg/ml by reference broth 
microdilution and screened for reduced susceptibility 
to vancomycin using PAP-AUC as the reference 
method, where they detected 15% h-VISA. They 
evaluated brain heart infusion (BHI) screen agar 
containing 16 g/liter casein and 4 mg/liter vancomycin 
for the detection of h-VISA, revealing 90% and 95% 
sensitivity and speciﬁcity with a 0.5 McFarland 
inoculum and 100% and 68% sensitivity and 
speciﬁcity with a 2.0 McFarland inoculum respectively 
[12].  
In the present work, adding casein to 
vancomycin screening agar increased detection rate of 
VISA by 4.5% (only one VISA out of 22). The base 
medium of the screening agar might be as important 
as the vancomycin concentration. Enhancement of 
detection of h-VISA by screen agar methods could be 
obtained by the addition of supplements to the agar. 
Willey et al. reported that the addition of pancreatic 
digest of casein to BHI agar and 4 g/ml vancomycin 
improved the detection of VISA on screen agars, as 
97.7% of VISA strains in their study were successfully 
detected with high speciﬁcity within 24 h [18]. Other 
supplement suggested differentiating between h-VISA 
and VSSA was the addition of 20% horse serum to 
BHI [19]. 
Riederer et al., tested 485 MRSA blood 
isolates with vancomycin MICs 0.5 to 4 µg/ml using 
BHI-V3, BHI-V4 and other methods. The modified 
PAP/AUC was measured for all isolates revealing 
seven VISA and 33 h-VISA phenotypes. The 
sensitivity and specificity for detecting VISA were 
100% and 94.6% for BHI-V3, 100% and 99.2%, for 
BHI-V4 respectively [20]. These observations differ 
from those of Burnham et al., who reported 100% 
C
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sensitivity and 65% speciﬁcity for detecting VISA with 
BHI-V3 [21]. The reason for the difference is unclear 
but might be related to isolates selection as Burnham 
et al., selected their isolates based on MIC results and 
did not perform PAP/AUC [21]. 
In the present study, screening agar with 6 
µg/ml vancomycin detected 7 out of 8 VISA with BMD 
MIC equal to 4 μg/ml (87.5%) with overall detection 
rate of VISA 95.45%. CDC 2015 stated that growth of 
more than one colony on screening agar with 6 μg/ml 
vancomycin is considered a positive result for VISA 
[13]. All S. aureus isolates for which the vancomycin 
MIC ≥ 8 µg/ml grow on these plates and some isolates 
for which the vancomycin MIC = 4 μg/ml will also grow 
[22].  
As a vancomycin MIC of 4 to 8 µg/ml is 
considered an intermediate susceptibility, the use of 
an agar medium such as BHI-V6 as a means to 
screen for vancomycin-intermediate strains of S. 
aureus (VISA) is not adequate for this purpose, as 
those strains having a vancomycin MIC greater than 2 
but less than 6 µg/ml could not be detected by this 
method [23]. 
Swenson et al. reported that BHI-V6 agar 
failed to detect 33% (12 of 36) of VISA isolates with 
MIC 4 µg/ml [24]. Similarly, Walsh et al. reported low 
sensitivity (22%) for the agar screening method using 
brain heart infusion agar (6 mg of vancomycin per 
litre), and 97% speciﬁcity [23].  
In the present study, the VITEK 2 system 
failed to detect any isolates with reduced susceptibility 
to vancomycin. Swenson et al. reported that the Vitek 
2 system tended to categorise VISA isolates as 
susceptible [24]. This was justified by Edwards et al., 
who demonstrated that MICs from automated systems 
and the E-test were significantly lower after 
cryopreservation if compared with those from the E-
test analysis, at the time of isolation [4]. Also, Mason 
et al. pointed out that the prevalence of vancomycin 
MIC creeps may be underestimated because of the 
cryopreservation effect [25]. 
On the other hand, the study performed by 
Burnham et al., showed that Vitek2 using card GP67 
had the worst sensitivity (7.7%), detecting only one 
out of the 13 VISA isolates compared to Microscan 
system which had the highest sensitivity (92%), 
followed by Etest (85% sensitive) and then Sensititre 
(54% sensitive). Thereby, they suggested that 
laboratories using the GP67 AST card for vancomycin 
susceptibility testing of S. aureus should consider 
additional testing to rule out VISA when MIC 2 µg/ml 
is generated and/or the concomitant use of a 
screening medium such as BHI-V3 to ensure 
detection of VISA isolates [21]. Also, Kruzel et al. 
stated that it became evident that the automated 
susceptibility testing methods are inappropriate for the 
detection of VISA [26]. 
All of our MRSA isolates were susceptible to 
vancomycin using VITEK 2 system. They were also 
sensitive to linezolid (100%) followed by tigecycline 
(99%) then Quinupristin-dalfopristin (91%). A study by 
Cook et al. described the successful treatment of a 
ventriculoperitoneal shunt infection caused by h-VISA 
with linezolid due to its tolerability and excellent blood-
brain barrier penetration [27]. High-dose of 
Quinupristin-dalfopristin (Synercid) significantly 
reduced the number of bacteria detected in the VISA 
hematogenous infection in murine models [28].  
Since the first reports of hVISA/VISA, their 
prevalence differed among geographic regions: the 
incidence of h-VISA was 6.81% in Asia and 5.60% in 
Europe/America, and that of VISA was 3.42% and 
2.75%, respectively. Several factors may be 
responsible for such condition; i) high public hygiene 
standards and meticulous antimicrobial treatments in 
most European and American countries [29], [30], 
[31], ii) the control of nosocomial infections is more 
successful in European and American countries [32, 
33], iii) Asia is the most populous region of the world, 
susceptible to microbial transmission, and iv) more 
MRSA infections occur in Asian countries [34].  
In the present work, Vancomycin screening 
agar; 2 µg/ml and (4 and 6 µg/ml) were able to detect; 
probable “pre hVISA and (hVISA and VISA) isolates 
respectively based on their broth microdilution MIC 
values. We believe that decreased vancomycin 
susceptibility in MRSA isolates might be related to 
MIC creep, but we could not indicate this 
phenomenon since an earlier data from our lab was 
not available for comparison. Similar factors as that 
found in Asia could be responsible for the occurrence 
of MRSA with reduced susceptibility to vancomycin in 
our country. Further studies on a large scale are 
needed to determine the prevalence of VISA and h-
VISA and also to study the phenomenon of 
vancomycin MIC creep. 
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